202 related articles for article (PubMed ID: 27715341)
1. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
Tramutola A; Arena A; Cini C; Butterfield DA; Barone E
Expert Rev Neurother; 2017 Jan; 17(1):59-75. PubMed ID: 27715341
[TBL] [Abstract][Full Text] [Related]
2. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
[TBL] [Abstract][Full Text] [Related]
3. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.
Bomba M; Granzotto A; Castelli V; Onofrj M; Lattanzio R; Cimini A; Sensi SL
J Alzheimers Dis; 2019; 70(3):793-810. PubMed ID: 31256135
[TBL] [Abstract][Full Text] [Related]
4. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
6. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
Hölscher C
Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
[No Abstract] [Full Text] [Related]
7. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
Duarte AI; Candeias E; Correia SC; Santos RX; Carvalho C; Cardoso S; Plácido A; Santos MS; Oliveira CR; Moreira PI
Biochim Biophys Acta; 2013 Apr; 1832(4):527-41. PubMed ID: 23314196
[TBL] [Abstract][Full Text] [Related]
8. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
9. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.
Bae CS; Song J
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165354
[TBL] [Abstract][Full Text] [Related]
10. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?
Hölscher C; Li L
Neurobiol Aging; 2010 Sep; 31(9):1495-502. PubMed ID: 18930564
[TBL] [Abstract][Full Text] [Related]
11. Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease.
Yildirim Simsir I; Soyaltin UE; Cetinkalp S
Diabetes Metab Syndr; 2018 May; 12(3):469-475. PubMed ID: 29598932
[TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
Wang XH; Yang W; Qi JS
Sheng Li Xue Bao; 2010 Oct; 62(5):398-406. PubMed ID: 20945041
[TBL] [Abstract][Full Text] [Related]
13. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
Calsolaro V; Edison P
CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
[TBL] [Abstract][Full Text] [Related]
14. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
Athauda D; Foltynie T
Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
[TBL] [Abstract][Full Text] [Related]
15. Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.
Pelle MC; Zaffina I; Giofrè F; Pujia R; Arturi F
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511061
[TBL] [Abstract][Full Text] [Related]
16. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
Hölscher C
J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
[TBL] [Abstract][Full Text] [Related]
17. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.
Talbot K; Wang HY
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S12-25. PubMed ID: 24529520
[TBL] [Abstract][Full Text] [Related]
18. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.
Li L
CNS Drugs; 2017 Jul; 31(7):535-549. PubMed ID: 28540646
[TBL] [Abstract][Full Text] [Related]
19. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
Hölscher C
Biochem Soc Trans; 2014 Apr; 42(2):593-9. PubMed ID: 24646283
[TBL] [Abstract][Full Text] [Related]
20. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
Gupta A; Bisht B; Dey CS
Neuropharmacology; 2011 May; 60(6):910-20. PubMed ID: 21277873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
